Ramsay Stuart C, Lindsay Karen, Fong William, Patford Shaun, Younger John, Atherton John
1Department of Nuclear Medicine and Specialised PET Service, Ned Hanlon Building, Royal Brisbane and Women's Hospital (RBWH), Herston, QLD 4029 Australia.
2School of Medicine, James Cook University, Douglas, QLD 4811 Australia.
Eur J Hybrid Imaging. 2018;2(1):17. doi: 10.1186/s41824-018-0035-1. Epub 2018 Aug 22.
99mTechnetium-HDP (HDP) bone scans differentiate transthyretin (ATTR) cardiac amyloid from other infiltrative myocardial diseases. These scans are not quantitative and are assessed by comparing myocardial uptake to bone. This study examined whether quantitative HDP SPECT/CT can discriminate individuals with cardiac ATTR from the population without this disease.
HDP thoracic xSPECT/CT QUANT (xQUANT) was performed in 29 patients: ATTR cardiac amyloid ( = 6); AL cardiac amyloid ( = 1); other infiltrative myocardial disease ( = 4); no known infiltrative cardiac disease ( = 18). SUVmax measured within volumes of interest for whole heart, ascending aorta blood pool, and specific bones. HDP myocardial uptake calculated as whole heart minus blood pool.
The cardiac ATTR group had greater HDP myocardial uptake than those with no known infiltrative disease ( = 0.002). AL and other myocardial diseases had uptake indistinguishable from the group with no known infiltrative cardiac disease. The SUVmaxima were sufficiently similar between individuals without cardiac ATTR that a 99% reference interval for HDP uptake could be calculated, providing an upper limit cut point of SUVmax 1.2. Individuals with cardiac ATTR had SUVmax well above this cut point.
Quantitative SPECT/CT can measure HDP myocardial uptake in individuals with normal hearts and those with cardiac ATTR without recourse to comparison with bone. It enables calculation of a reference interval for HDP myocardial uptake in the population without ATTR cardiac amyloid. Using this reference interval single individuals with cardiac ATTR can be accurately discriminated from the non-affected population. This technique uses a NIST traceable calibration source, potentially allowing development of multicentre clinical decision limits. Its role in disease management warrants further assessment.
锝-99m 焦膦酸盐(HDP)骨扫描可区分转甲状腺素蛋白(ATTR)心脏淀粉样变与其他浸润性心肌疾病。这些扫描不是定量的,而是通过比较心肌摄取与骨骼摄取来评估。本研究探讨了定量 HDP SPECT/CT 是否能够将患有心脏ATTR的个体与无此病的人群区分开来。
对 29 例患者进行了 HDP 胸部 xSPECT/CT 定量分析(xQUANT):ATTR 心脏淀粉样变(n = 6);AL 心脏淀粉样变(n = 1);其他浸润性心肌疾病(n = 4);无已知浸润性心脏病(n = 18)。在全心脏、升主动脉血池和特定骨骼的感兴趣区内测量 SUVmax。HDP 心肌摄取量计算为全心脏摄取量减去血池摄取量。
心脏ATTR组的 HDP 心肌摄取量高于无已知浸润性疾病的组(P = 0.002)。AL 和其他心肌疾病的摄取量与无已知浸润性心脏病的组无明显差异。无心脏ATTR的个体之间的 SUVmax 足够相似,因此可以计算出 HDP 摄取的 99%参考区间,得出 SUVmax 的上限切点为 1.2。患有心脏ATTR的个体的 SUVmax 远高于此切点。
定量 SPECT/CT 可以测量正常心脏个体和患有心脏ATTR个体的 HDP 心肌摄取量,而无需与骨骼进行比较。它能够计算出无ATTR心脏淀粉样变人群中 HDP 心肌摄取的参考区间。使用该参考区间,可以准确地将患有心脏ATTR的个体与未受影响的人群区分开来。该技术使用了美国国家标准与技术研究院(NIST)可溯源的校准源,有可能制定多中心临床决策限值。其在疾病管理中的作用值得进一步评估。